U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H36N4O11.2H2O4S
Molecular Weight 680.656
Optical Activity UNSPECIFIED
Defined Stereocenters 15 / 15
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of KANAMYCIN ACID SULFATE

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.[H][C@]3(O[C@H]1[C@H](N)C[C@H](N)[C@@H](O[C@@]2([H])O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@@H]1O)O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O

InChI

InChIKey=OGTKIXVMLDAMNU-KNQICTBBSA-N
InChI=1S/C18H36N4O11.2H2O4S/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17;2*1-5(2,3)4/h4-18,23-29H,1-3,19-22H2;2*(H2,1,2,3,4)/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-;;/m1../s1

HIDE SMILES / InChI
Kanamycin A is aminoglycoside anti-bacterial agent. Active against many strains of Gram-negative bacteria and Gram-positive Staphylococcus aureus and epidermis. Some strains of Mycobacterium bacterium are sensitive. Most active in alkaline solution. It binds to bacterial ribosomes and reduces mRNA translation hence reduces protein biosynthesis. However, it also exhibits some toxic effects towards mammalian cells.

CNS Activity

Curator's Comment: In adults, does not cross the blood-brain barrier (BBB) in therapeutically adequate concentrations. Small improvement in penetration with inflamed meninges. Higher levels are achieved in the CSF of newborns than in adults.

Originator

Curator's Comment: Kanamycin isolation: https://www.ncbi.nlm.nih.gov/pubmed/13513509 Kanamycin A synthesis: https://www.ncbi.nlm.nih.gov/pubmed/4973123

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
PubMed

PubMed

TitleDatePubMed
[Clinical use of vitamin K-1 in hearing disorders caused by kanamycin].
1966 Apr
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain.
1967 Jul
Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.
1967 May
Unusual neurotoxicity of kanamycin.
1967 May 1
[Clinical studies of cochleotoxicosis due to viomycin and kanamycin during tuberculostatic treatment (a prophylactic attempt)].
1968
[Recovery after hemodialysis in 2 cases of acute renal insufficiency during treatment with kanamycin and colistin methanesulfonate].
1970 Apr 27
[Hearing damages in prolonged kanamycin therapy].
1970 Aug
[Studies on nephrotoxicity of combined administration of kanamycin and sodium alginate].
1970 Jun
Kanamycin ototoxicity--possible potentiation by other drugs.
1970 May
[Severe hearing disorders caused by kanamycin].
1970 Sep
[Biochemical studies on nephrotoxicity of kanamycin].
1971 Feb
Acute renal failure in general surgical patients.
1971 Jun
Laboratory testing for ototoxic effects of drugs.
1973 Jun
Protein synthesis in Mycobacterium tuberculosis H37Rv and the effect of streptomycin in streptomycin-susceptible and -resistant strains.
1973 Sep
Nephropathy, an underestimated complication of methicillin therapy.
1974 Jun
Proceedings: The use of conditioned tone discrimination to study kanamycin ototoxicity in the rat.
1975 Dec
The quantification of kanamycin ototoxicity in the rat using conditioned tone discrimination.
1975 Dec
[On the mechanism of kanamycin ototoxicity (II): --Alteration of glucose metabolism in cochlea and kidney (author's transl)].
1977 Jan 20
Drug-induced anaphylaxis, convulsions, deafness, and extrapyramidal symptoms.
1977 Mar 12
[Amikacin and kanamycin. Comparative experimental studies on nephrotoxicity].
1978
Auditory thresholds and kanamycin-induced hearing loss in the guinea pig assessed by a positive reinforcement procedure.
1978 Feb
Potentiation of neuromuscular weakness in infant botulism by aminoglycosides.
1979 Dec
Quantitative relationships of the ototoxic interaction of kanamycin and ethacrynic acid.
1979 May
[Detection of auditory impairment in the offsprings caused by drug treatment of the dams].
1982 Dec
In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin.
1982 Sep
Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.
1984
[Measurement of an auditory impairment induced by aminoglycosides using a shuttle box method in newborn rats].
1985 Dec
In vitro antituberculosis activity of a new antibacterial substance ofloxacin (DL8280).
1985 Mar
Reflex modification as a test for sensory function.
1985 Nov-Dec
Furosemide ototoxicity: clinical and experimental aspects.
1985 Sep
Mycobacterial plasmids: screening and possible relationship to antibiotic resistance in Mycobacterium avium/Mycobacterium intracellulare.
1986
Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex.
1987
In vitro susceptibility of Mycobacterium avium complex to antibacterial agents.
1987 Nov
MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs.
1988 Aug
[Experimental study of drug-induced acute renal failure. Recovery after renal impairment caused by the administration of low molecular weight dextran and kanamycin in water-deprived rats].
1988 Feb
[Bilateral deafness after intra-lumbar administration of kanamycin].
1988 Jul-Aug
Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare.
1988 Mar-Apr
Qualitative and quantitative drug-susceptibility tests in mycobacteriology.
1988 May
Nephrotoxicity of dactimicin, a novel pseudo-disaccharide aminoglycoside possessing the N-formimidoyl group, compared with that of astromicin, amikacin and other aminoglycoside antibiotics in animals.
1989
[Drug-induced nephropathy and hemorrhagic cystitis as an adverse reaction to kanamycin].
1989 Aug
Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis.
1989 Aug
New antibiotics, resorcinomycins A and B: antibacterial activity of resorcinomycin A against mycobacteria in vitro.
1989 Mar
[Prevention of neurosensory hearing disorders in antibiotic-induced ototoxicosis].
1989 Mar-Apr
[Acute renal failure caused by ceporin, kanamycin and gentamicin].
1989 Mar-Apr
Amyloid-like protein inclusions in tobacco transgenic plants.
2010 Oct 26
The multifunctional host defense peptide SPLUNC1 is critical for homeostasis of the mammalian upper airway.
2010 Oct 7
Conservation of endocochlear potential in mice with profound hearing loss induced by co-administration of kanamycin and furosemide.
2011 Apr
Dominant incidence of multidrug and extensively drug-resistant specific Mycobacterium tuberculosis clones in Osaka Prefecture, Japan.
2012
Mitochondrial peroxiredoxin 3 regulates sensory cell survival in the cochlea.
2013
Potent activity against multidrug-resistant Mycobacterium tuberculosis of α-mangostin analogs.
2013
Patents

Sample Use Guides

10 to 50 uM
Route of Administration: Other
Rabbit reticulocyte ribosomes were used to investigate the activities of kanamycin A on higher eukaryotic ribosomes. The drug-mediated inhibition of protein synthesis by determining IC50 values in translation of luciferase mRNA was assessed. The IC50 for Kanamycin A is 126.85 uM. eukaryotic protein synthesis.
Name Type Language
KANAMYCIN ACID SULFATE
WHO-IP  
Common Name English
KANAMYCINI SULFAS ACIDUS [WHO-IP LATIN]
Common Name English
D-STREPTAMINE, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4))-2-DEOXY-, SULFATE (1:2) (SALT)
Systematic Name English
KANAMYCIN ACID SULFATE [WHO-IP]
Common Name English
KANAMYCIN ACID SULFATE [EP MONOGRAPH]
Common Name English
KANAMYCIN DISULFATE
Common Name English
KANAMYCIN A DISULFATE
Common Name English
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
KANAMYCIN ACID SULFATE
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY Description: White or almost white powder.Solubility: Freely soluble in water, practically insoluble in acetone R or ethanol (~750 g/l) TS. Category: Antibacterial. Storage: Kanamycin acid sulfate should be kept in a tightly closed container, or if sterile, in a hermetically closed container. Labelling: The label states: - the content in terms of IU per mg, calculated with reference to the dried substance, - where applicable, that the substances is free from bacterial endotoxins, - where applicable, that the substance is sterile.Additional information: Kanamycin acid sulfate is hygroscopic. Definition: Kanamycin acid sulfate is a form of kanamycin sulfate prepared by adding sulfuric acid to a solution of Kanamycin monosulfate or kanamycin and drying by a suitable method; Kanamycin acid sulfate, Kanamycin monosulfate and kanamycin are produced by fermentation. Kanamycin acid sulfate contains not less than 670 International Units per mg, with reference to the dried substance.
EPA CompTox
DTXSID00641058
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY
CHEBI
6109
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY
PUBCHEM
24721551
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY
FDA UNII
1KF3N5C3AK
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY
CAS
64013-70-3
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY
EVMPD
SUB12092MIG
Created by admin on Sat Dec 16 10:14:38 GMT 2023 , Edited by admin on Sat Dec 16 10:14:38 GMT 2023
PRIMARY